Thyrocare Technologies (NSE:THYROCARE) Beneish M-Score: -2.79 (As of Jun. 29, 2026)


NSE:THYROCARE Thyrocare Technologies Ltd NSE:THYROCARE
87 GF Score
Price ₹524.40
GF Value ₹391.69
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Thyrocare Technologies Beneish M-Score?

Thyrocare Technologies NSE:THYROCARE +1.39% 87 Beneish M-Score is -2.79 as of Jun. 29, 2026. GuruFocus rates NSE:THYROCARE with a GF Score™ of 87/100 and a GF Value™ of ₹391.69 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 194 Medical Diagnostics & Research companies, Thyrocare Technologies ranks better than 62.37% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.79 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Thyrocare Technologies's Beneish M-Score or its related term are showing as below:

NSE:THYROCARE' s Beneish M-Score Range Over the Past 10 Years
Min: -3.97   Med: -2.64   Max: -0.77
Current: -2.79

During the past 13 years, the highest Beneish M-Score of Thyrocare Technologies was -0.77. The lowest was -3.97. And the median was -2.64.


Thyrocare Technologies Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Thyrocare Technologies's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Thyrocare Technologies Beneish M-Score Chart

Thyrocare Technologies Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.25 -3.09 -3.76 -2.49 -2.79

Thyrocare Technologies Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.49 0.00 0.00 0.00 -2.79

NSE:THYROCARE vs TMO, DHR, IDXX: Beneish M-Score Comparison

For the Diagnostics & Research subindustry, Thyrocare Technologies's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Thyrocare Technologies Beneish M-Score vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Thyrocare Technologies's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Thyrocare Technologies's Beneish M-Score falls into.


NSE:THYROCARE
87GF Score
Thyrocare Technologies Ltd NSE:THYROCARE
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Thyrocare Technologies Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Thyrocare Technologies for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.8205+0.528 * 0.9813+0.404 * 0.9834+0.892 * 1.2074+0.115 * 0.9943
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 1.0077+4.679 * -0.067182-0.327 * 0.9961
=-2.79

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Total Receivables was ₹820 Mil.
Revenue was ₹8,219 Mil.
Gross Profit was ₹6,023 Mil.
Total Current Assets was ₹3,723 Mil.
Total Assets was ₹7,472 Mil.
Property, Plant and Equipment(Net PPE) was ₹2,087 Mil.
Depreciation, Depletion and Amortization(DDA) was ₹586 Mil.
Selling, General, & Admin. Expense(SGA) was ₹942 Mil.
Total Current Liabilities was ₹1,099 Mil.
Long-Term Debt & Capital Lease Obligation was ₹392 Mil.
Net Income was ₹1,630 Mil.
Gross Profit was ₹0 Mil.
Cash Flow from Operations was ₹2,132 Mil.
Total Receivables was ₹828 Mil.
Revenue was ₹6,807 Mil.
Gross Profit was ₹4,896 Mil.
Total Current Assets was ₹3,377 Mil.
Total Assets was ₹6,928 Mil.
Property, Plant and Equipment(Net PPE) was ₹1,983 Mil.
Depreciation, Depletion and Amortization(DDA) was ₹553 Mil.
Selling, General, & Admin. Expense(SGA) was ₹774 Mil.
Total Current Liabilities was ₹1,218 Mil.
Long-Term Debt & Capital Lease Obligation was ₹169 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(820.1 / 8218.9) / (827.8 / 6807.1)
=0.099782 / 0.121608
=0.8205

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(4895.5 / 6807.1) / (6023.2 / 8218.9)
=0.719176 / 0.732847
=0.9813

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (3722.9 + 2086.8) / 7472.2) / (1 - (3377.2 + 1983) / 6927.5)
=0.222491 / 0.226243
=0.9834

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=8218.9 / 6807.1
=1.2074

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(552.6 / (552.6 + 1983)) / (585.8 / (585.8 + 2086.8))
=0.217937 / 0.219187
=0.9943

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(942 / 8218.9) / (774.2 / 6807.1)
=0.114614 / 0.113734
=1.0077

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((391.8 + 1099.1) / 7472.2) / ((169.2 + 1218.4) / 6927.5)
=0.199526 / 0.200303
=0.9961

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(1630.4 - 0 - 2132.4) / 7472.2
=-0.067182

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Thyrocare Technologies has a M-score of -2.79 suggests that the company is unlikely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of -2.79 mean?
Thyrocare Technologies (NSE:THYROCARE) has a Beneish M-Score of -2.79 as of Jun. 29, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Thyrocare Technologies and its competitors. According to the industry distribution chart, Thyrocare Technologies ranks #73 out of 194 companies in the Medical Diagnostics & Research industry, placing it in the top 37.6%.
Is Thyrocare Technologies' Beneish M-Score too high?
Thyrocare Technologies' current Beneish M-Score is -2.79. Based on the distribution chart, Thyrocare Technologies ranks #73 out of 194 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Thyrocare Technologies has a GF Score™ of 87/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Thyrocare Technologies' Beneish M-Score compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Thyrocare Technologies ranks #73 out of 194 companies for Beneish M-Score. This puts Thyrocare Technologies in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Medical Diagnostics & Research company?
A good Beneish M-Score depends on the Medical Diagnostics & Research industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Thyrocare Technologies and its competitors. Thyrocare Technologies's current Beneish M-Score is -2.79. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Thyrocare Technologies stock overvalued right now?
Based on GuruFocus' analysis, Thyrocare Technologies (NSE:THYROCARE) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹391.69, compared to a current price of ₹524.40 — trading 33.9% above its estimated fair value. The current Beneish M-Score is -2.79. Thyrocare Technologies' overall GF Score™ is 87/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Thyrocare Technologies (NSE:THYROCARE), the current Beneish M-Score is -2.79 as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Thyrocare Technologies (NSE:THYROCARE) Overvalued in 2026?

Based on GuruFocus' analysis, Thyrocare Technologies stock appears to be overvalued. The current stock price of ₹524.40 is trading 33.9% above its estimated GF Value™ of ₹391.69. GuruFocus considers Thyrocare Technologies to be Significantly Overvalued.

Key valuation signals for NSE:THYROCARE:

  • Beneish M-Score: -2.79
  • GF Value™: ₹391.69 vs. price of ₹524.40 (33.9% above fair value)
  • GF Score™: 87/100 with 5 warning signs

No single metric tells the full story. See the NSE:THYROCARE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Thyrocare Technologies Business Description

Other Exchanges 539871:India
Address D-37/3, TTC Industrial Area, MIDC, Turbhe, Opposite Sandoz, Navi Mumbai, MH, IND, 400703
Thyrocare Technologies Ltd is a diagnostics & research company. The company has three business segments: Diagnostic Testing Services, Imaging Services, and Others: Sale of testing equipment and consumables. The Diagnostic Testing Services segment provides Diagnostic and testing services, selling of consumables used for the collection and promotion of the pathology segment. The company majorly earns the majority of its revenue from the Diagnostic Testing Services segment. The Imaging Services segment operates Diagnostic and imaging services, selling of radio-pharmaceuticals, and selling of consumables for reporting. The Other business segment is engaged in the selling of glucometers and glucostrips under the brand name Sugarscan. The company earns the vast majority of its revenue in India.
87GF Score

Get the complete analysis for NSE:THYROCARE

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹524.40
Price
₹391.69
GF Value